Barnard Sunelle A, Pieters Marlien, De Lange Zelda
Centre of Excellence for Nutrition, North-West University, Potchefstroom, South Africa.
Blood Rev. 2016 Nov;30(6):421-429. doi: 10.1016/j.blre.2016.05.002. Epub 2016 May 19.
Increased plasma plasminogen activator inhibitor-1 (PAI-1) level is considered a mechanistic pathway through which obesity contributes to increased cardiovascular disease risk. Abdominal adipose tissue specifically, is a major PAI-1 source with visceral adipose tissue (VAT), an ectopic fat depot, generally considered to produce more PAI-1 than subcutaneous adipose tissue. However, this does not necessarily lead to increased plasma PAI-1 levels. This review provides an overview of studies investigating the association between body fat distribution and plasma PAI-1 levels. It discusses factors that influence this relationship and also considers the contribution of other tissue to plasma PAI-1 levels, placing the relative contribution of adipose tissue into perspective. In conclusion, the relationship between VAT and plasma PAI-1 levels is not fixed but can be modulated by a number of factors such as the size of the subcutaneous adipose tissue depot, ethnicity, possibly genetics and other obesity-related metabolic abnormalities.
血浆纤溶酶原激活物抑制剂-1(PAI-1)水平升高被认为是肥胖导致心血管疾病风险增加的一种机制途径。特别是腹部脂肪组织,是PAI-1的主要来源,内脏脂肪组织(VAT)作为一个异位脂肪库,通常被认为比皮下脂肪组织产生更多的PAI-1。然而,这并不一定会导致血浆PAI-1水平升高。本综述概述了研究体脂分布与血浆PAI-1水平之间关联的研究。它讨论了影响这种关系的因素,还考虑了其他组织对血浆PAI-1水平的贡献,从而正确看待脂肪组织的相对贡献。总之,VAT与血浆PAI-1水平之间的关系不是固定不变的,而是可以受到多种因素的调节,如皮下脂肪组织库的大小、种族、可能还有遗传学以及其他与肥胖相关的代谢异常。